GlassScriptPhysician profile
Ledya Cobian
NPI 1619973377
$20,154.94
in general payments reported to CMS, 2019-2025
24 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what 87% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,693 · 2020: $2,645 · 2021: $3,527 · 2022: $2,794 · 2023: $3,531 · 2024: $2,464 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,487 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,487.15 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,494.94 | 2019-2025 | Biktarvy, Veklury |
| Viiv Healthcare Company | $4,786.14 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Janssen Biotech, INC. | $2,126.53 | 2019-2023 | Symtuza, Prezcobix |
| Insmed, INC. | $1,779.03 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $1,443.02 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $1,313.50 | 2019-2025 | Dalvance, Avycaz, Mavyret |
| Emd Serono, INC. | $575.04 | 2019-2025 | Serostim |
| Melinta Therapeutics, LLC | $499.67 | 2019-2024 | Kimyrsa, Orbactiv, Rezzayo |
| Paratek Pharmaceuticals, INC. | $409.21 | 2020-2025 | Nuzyra |
| Shionogi INC | $359.67 | 2020-2025 | Fetroja |
| Astellas Pharma US INC | $287.91 | 2019-2022 | |
| Allergan, INC. | $287.23 | 2019-2020 | |
| Theratechnologies INC. | $202.58 | 2022-2025 | Egrifta, Trogarzo |
| Janssen Products, LP | $191.98 | 2019-2021 | |
| Medtronic, INC. | $156.01 | 2023 | Micra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $50.55 | 2023-2024 | Xacduro, Xerava |
| Mylan Institutional INC. | $42.07 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $32.39 | 2025 | Vibativ |
| Tetraphase Pharmaceuticals, INC. | $28.18 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $27.04 | 2021 | |
| Aimmune Therapeutics, INC. | $20.47 | 2024 | |
| Janssen Scientific Affairs, LLC | $15.83 | 2023 | Symtuza |
| Mylan Pharmaceuticals INC. | $14.38 | 2019 | |
| Seqirus USA INC | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ledya Cobian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.